TY - JOUR
T1 - Endovascular revascularization of renal artery stenosis in the solitary functioning kidney
AU - Davies, Mark G.
AU - Saad, Wael E.
AU - Bismuth, Jean X.
AU - Naoum, Joseph J.
AU - Peden, Eric K.
AU - Lumsden, Alan B.
PY - 2009/4
Y1 - 2009/4
N2 - Background: Endovascular therapy for symptomatic atherosclerotic renal artery stenosis (ARAS) is considered effective. This study evaluates the factors that impact long term anatomic and functional outcomes of endovascular therapy of ARAS in patients with a solitary functioning kidney. Methods: We performed a retrospective analysis of records from patients who underwent endovascular intervention for ARAS and identified patients with a solitary functioning kidney (absent or nonfunctioning contralateral kidney) and patients with contralateral normal kidney (for comparison) between January 1990 and January 2008. Indications for intervention in the solitary functioning kidney were poorly controlled hypertension (diastolic blood pressure [BP] >90 mm Hg on >3 antihypertensive medications) and/or elevated creatinine (Cr ≥1.5 mg/dL). Clinical benefit was defined as freedom from composite recurrent symptoms (recurrent hypertension or renal-related morbidity-increase in persistent creatinine >20% of baseline, progression to hemodialysis, and death from renal-related causes), anatomic patency and patient survival were measured. Results: A total of 242 patients (56% male, average age 69 years, range, 45-90) underwent angioplasty (23%) or primary stenting (77%) of a single renal artery with a normal contralateral renal vessel and kidney and 73 patients (58% male, average age 70 years, range, 52-89) underwent angioplasty (37%) or primary stenting (63%) for a solitary functioning kidney. There were no significant differences in mortality or morbidity between the groups. There was a significant difference in the long-term survival with 55 ± 8% patients with a normal contralateral kidney vs 27 ± 7% patients with a solitary functioning kidney alive at 10 years. Clinical benefit was 67 ± 6% and 67 ± 4% at 5 years and 63 ± 8% and 62 ± 4% at 10 years for solitary functioning kidney and normal contralateral groups, respectively. Using proportional hazard analysis, the predictors of long-term clinical benefit were ipsilateral kidney size (>9 cm), no immediate deterioration in function, and an estimated Glomerular Filtration Rate (eGFR) >30 mL/min/1.73m2. Neither control of diabetes nor the administration of statins was shown to influence outcomes in the solitary functioning kidney. Conclusion: Intervention in patients with a solitary functioning kidney is a safe procedure and improves or stabilizes renal function in 82% of patients. Clinical benefit is dictated by preoperative GFR, renal size, and the occurrence of acute functional injury after the procedure.
AB - Background: Endovascular therapy for symptomatic atherosclerotic renal artery stenosis (ARAS) is considered effective. This study evaluates the factors that impact long term anatomic and functional outcomes of endovascular therapy of ARAS in patients with a solitary functioning kidney. Methods: We performed a retrospective analysis of records from patients who underwent endovascular intervention for ARAS and identified patients with a solitary functioning kidney (absent or nonfunctioning contralateral kidney) and patients with contralateral normal kidney (for comparison) between January 1990 and January 2008. Indications for intervention in the solitary functioning kidney were poorly controlled hypertension (diastolic blood pressure [BP] >90 mm Hg on >3 antihypertensive medications) and/or elevated creatinine (Cr ≥1.5 mg/dL). Clinical benefit was defined as freedom from composite recurrent symptoms (recurrent hypertension or renal-related morbidity-increase in persistent creatinine >20% of baseline, progression to hemodialysis, and death from renal-related causes), anatomic patency and patient survival were measured. Results: A total of 242 patients (56% male, average age 69 years, range, 45-90) underwent angioplasty (23%) or primary stenting (77%) of a single renal artery with a normal contralateral renal vessel and kidney and 73 patients (58% male, average age 70 years, range, 52-89) underwent angioplasty (37%) or primary stenting (63%) for a solitary functioning kidney. There were no significant differences in mortality or morbidity between the groups. There was a significant difference in the long-term survival with 55 ± 8% patients with a normal contralateral kidney vs 27 ± 7% patients with a solitary functioning kidney alive at 10 years. Clinical benefit was 67 ± 6% and 67 ± 4% at 5 years and 63 ± 8% and 62 ± 4% at 10 years for solitary functioning kidney and normal contralateral groups, respectively. Using proportional hazard analysis, the predictors of long-term clinical benefit were ipsilateral kidney size (>9 cm), no immediate deterioration in function, and an estimated Glomerular Filtration Rate (eGFR) >30 mL/min/1.73m2. Neither control of diabetes nor the administration of statins was shown to influence outcomes in the solitary functioning kidney. Conclusion: Intervention in patients with a solitary functioning kidney is a safe procedure and improves or stabilizes renal function in 82% of patients. Clinical benefit is dictated by preoperative GFR, renal size, and the occurrence of acute functional injury after the procedure.
UR - http://www.scopus.com/inward/record.url?scp=63049095365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63049095365&partnerID=8YFLogxK
U2 - 10.1016/j.jvs.2008.11.042
DO - 10.1016/j.jvs.2008.11.042
M3 - Article
C2 - 19217744
AN - SCOPUS:63049095365
SN - 0741-5214
VL - 49
SP - 953
EP - 960
JO - Journal of Vascular Surgery
JF - Journal of Vascular Surgery
IS - 4
ER -